The ongoing CODEL phase III trial evaluates newly-diagnosed patients with IDH mutant, 1p/19q co-deleted gliomas grades 2 and 3, and compares the use of radiation followed by PCV versus radiation with concurrent temozolomide followed by adjuvant temozolomide [66]. Here, IDH2 is linked to central nervous system cancer.